Yuan Qiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuan Qiu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Qing Ai
Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health
2 shared publicationsAi Qing
Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China
1 shared publicationChen Xu
Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China
1 shared publicationDan Liu
Department of Thoracic Surgery, Anhui Chest Hospital, Anhui, China
1 shared publication- Dong-Yun He
Department of Thoracic Oncology, The First Affiliated Hospital, Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, National Clinical Research Center of Respiratory Disease, Guangzhou, China
1 shared publication - Haihong Yang
Department of Thoracic Oncology, The First Affiliated Hospital, Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, National Clinical Research Center of Respiratory Disease, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 7 September 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1855116
Heterogeneity of thromboembolic risk across ALK inhibitors: a retrospective real-world study identifying crizotinib-specific signals and high-risk subpopulations
Background: Patients with anaplastic lymphoma kinase (ALK)-positive malignancies increasingly rely on ALK inhibitors (ALKis) as first-line therapy, yet thromboembolism (TE) across the ALKi family and its impact on patients’ safety remain incompletely characterized, particularly in the real-world populations. Objective: The aim of this study was to evaluate the real-world TE risks associated with ALKis using pharmacovigilance data mining and to identify and characterize the high-risk contributors to TE. Methods: We extracted 52,808 adverse event (AE) reports from the FDA Adverse Event Reporting System (2013–2024), including 17,124 ALKi-treated patients. TE signal strength was calculated via disproportionality analysis and presented by the lower limit of reporting odds ratio (ROR 025 ) and information component (IC 025 ). Multivariate logistic regression and time-to-onset (TTO) analyses were conducted to characterize the risk factors. Results: Among ALKi users, 251 TE cases were identified. Crizotinib exhibited significant TE safety signals for embolism (ROR 025 = 2.66; IC0 25 = 1.19), pulmonary artery thrombosis (ROR 025 = 4.94; IC0 25 = 1.01), pulmonary thrombosis (ROR 025 = 1.29; IC0 25 = 0.13), and venous thrombosis limb (ROR 025 = 1.66; IC0 25 = 0.08). Older age (OR = 1.006, P = 2.40e-06), male sex (OR = 1.47, P = 2.00e-16), and crizotinib use (OR = 2.79, P = 1.59e-05) independently predicted fatal TE outcomes. Female patients <65 years experienced earlier TE onset (median 14 vs. 44–53 days; P = 0.006). Conclusion: This study validates the elevated TE safety signal strength of crizotinib in the real-world settings, while no disproportionate TE signals were detected for other ALKi in the FAERS database. Clinicians could prioritize agent-specific risks, especially in older male patients and during early treatment phases.
- 7 September 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1855116
Open AccessHeterogeneity of thromboembolic risk across ALK inhibitors: a retrospective real-world study identifying crizotinib-specific signals and high-risk subpopulations
Background: Patients with anaplastic lymphoma kinase (ALK)-positive malignancies increasingly rely on ALK inhibitors (ALKis) as first-line therapy, yet thromboembolism (TE) across the ALKi family and its impact on patients’ safety remain incompletely characterized, particularly in the real-world populations. Objective: The aim of this study was to evaluate the real-world TE risks associated with ALKis using pharmacovigilance data mining and to identify and characterize the high-risk contributors to TE. Methods: We extracted 52,808 adverse event (AE) reports from the FDA Adverse Event Reporting System (2013–2024), including 17,124 ALKi-treated patients. TE signal strength was calculated via disproportionality analysis and presented by the lower limit of reporting odds ratio (ROR 025 ) and information component (IC 025 ). Multivariate logistic regression and time-to-onset (TTO) analyses were conducted to characterize the risk factors. Results: Among ALKi users, 251 TE cases were identified. Crizotinib exhibited significant TE safety signals for embolism (ROR 025 = 2.66; IC0 25 = 1.19), pulmonary artery thrombosis (ROR 025 = 4.94; IC0 25 = 1.01), pulmonary thrombosis (ROR 025 = 1.29; IC0 25 = 0.13), and venous thrombosis limb (ROR 025 = 1.66; IC0 25 = 0.08). Older age (OR = 1.006, P = 2.40e-06), male sex (OR = 1.47, P = 2.00e-16), and crizotinib use (OR = 2.79, P = 1.59e-05) independently predicted fatal TE outcomes. Female patients <65 years experienced earlier TE onset (median 14 vs. 44–53 days; P = 0.006). Conclusion: This study validates the elevated TE safety signal strength of crizotinib in the real-world settings, while no disproportionate TE signals were detected for other ALKi in the FAERS database. Clinicians could prioritize agent-specific risks, especially in older male patients and during early treatment phases.
- Open Access
- 27 February 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1744202
Persistent lactic acidosis in ALK-positive anaplastic large cell lymphoma: a case report and literature review
Lactic acidosis is common in the ICU, but malignancy-associated type B lactic acidosis mediated by the clinical Warburg effect (CWE) is uncommon and easily missed when infection or organ dysfunction dominates the presentation. We report a 35-year-old man with a month of fever and progressive dyspnea who presented with persistent hyperlactatemia (peak 15.46 mmol/L) and markedly elevated LDH despite stable hemodynamics. Imaging revealed generalized lymphadenopathy, multifocal osteolytic lesions, and bilateral pleural effusions; infectious studies were unrevealing apart from chronic hepatitis B. Cervical node biopsy (CD30 + , ALK-L + , EMA + ; Ki-67 ~80%; EBER–; pan-B/T and epithelial markers negative) established ALK-positive anaplastic large-cell lymphoma. In the absence of shock or sustained hypoperfusion, CWE/type B lactic acidosis was diagnosed. An etoposide-containing CHOP variant (ECHOP/CHOEP, days 1–5) was initiated with parallel continuous renal replacement therapy (CVVHDF) to stabilize acid–base and electrolytes as a bridge to chemotherapy. Lactate declined from 13.30 mmol/L immediately before chemotherapy to 2.88 mmol/L by day 3, 1.33 mmol/L by day 8, and normalized (0.6 mmol/L) by day 17, closely tracking clinical improvement. The patient was extubated, CRRT discontinued, transferred out of the ICU, and discharged; chemotherapy-related myelosuppression and ICU-acquired weakness were managed with G-CSF, transfusions, and early rehabilitation, and a femoral deep-vein thrombosis was treated with anticoagulation. A focused review of 18 recent case reports (2021–2025) suggests that timely, standardized antitumor therapy is frequently followed by a rapid, time-locked fall in lactate, whereas the absence of definitive oncologic treatment portends uniformly poor short-term outcomes. This case underscores that, in hemodynamically stable patients with refractory hyperlactatemia, early consideration of CWE and prompt tumor-directed therapy—supported by targeted organ support such as CRRT—offer the most reliable path to metabolic reversal and recovery.
- 27 February 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1744202
Open AccessPersistent lactic acidosis in ALK-positive anaplastic large cell lymphoma: a case report and literature review
Lactic acidosis is common in the ICU, but malignancy-associated type B lactic acidosis mediated by the clinical Warburg effect (CWE) is uncommon and easily missed when infection or organ dysfunction dominates the presentation. We report a 35-year-old man with a month of fever and progressive dyspnea who presented with persistent hyperlactatemia (peak 15.46 mmol/L) and markedly elevated LDH despite stable hemodynamics. Imaging revealed generalized lymphadenopathy, multifocal osteolytic lesions, and bilateral pleural effusions; infectious studies were unrevealing apart from chronic hepatitis B. Cervical node biopsy (CD30 + , ALK-L + , EMA + ; Ki-67 ~80%; EBER–; pan-B/T and epithelial markers negative) established ALK-positive anaplastic large-cell lymphoma. In the absence of shock or sustained hypoperfusion, CWE/type B lactic acidosis was diagnosed. An etoposide-containing CHOP variant (ECHOP/CHOEP, days 1–5) was initiated with parallel continuous renal replacement therapy (CVVHDF) to stabilize acid–base and electrolytes as a bridge to chemotherapy. Lactate declined from 13.30 mmol/L immediately before chemotherapy to 2.88 mmol/L by day 3, 1.33 mmol/L by day 8, and normalized (0.6 mmol/L) by day 17, closely tracking clinical improvement. The patient was extubated, CRRT discontinued, transferred out of the ICU, and discharged; chemotherapy-related myelosuppression and ICU-acquired weakness were managed with G-CSF, transfusions, and early rehabilitation, and a femoral deep-vein thrombosis was treated with anticoagulation. A focused review of 18 recent case reports (2021–2025) suggests that timely, standardized antitumor therapy is frequently followed by a rapid, time-locked fall in lactate, whereas the absence of definitive oncologic treatment portends uniformly poor short-term outcomes. This case underscores that, in hemodynamically stable patients with refractory hyperlactatemia, early consideration of CWE and prompt tumor-directed therapy—supported by targeted organ support such as CRRT—offer the most reliable path to metabolic reversal and recovery.
- Open Access
- 28 May 2024
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 2 (4) , 633-635
Subsuperior Segment Segmentectomy
- 28 May 2024
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 2 (4) , 633-635
Open AccessSubsuperior Segment Segmentectomy
- Open Access
- 31 October 2022
- Published by Hindawi Limited in Canadian Respiratory Journal
- Vol. 2022, 1-5
Efficacy of Intrapleural or Intrapericardial Injection of Single Bevacizumab in the Treatment of Lung Cancer-Mediated Malignant Effusion
The usage of bevacizumab for malignant pleural effusion (MPE) or malignant pericardial effusion (MPCE) has attracted increasing interest from researchers, but the precise ways of bevacizumab administration remain unknown. Patients with histologically or cytologically confirmed non-small-cell lung cancer (NSCLC) with MPE or MPCE were enrolled in the study and treated with a low dose of single bevacizumab (100 mg) intrapleurally or intrapericardially injected after the drainage of the effusions. The Lung Cancer Symptom Scale (LCSS), efficacy, and safety of drug administration were used as evaluation parameters in this study. The results indicated that lung cancer-related symptoms were significantly improved following treatment, compared with symptoms before the treatment (LCSS, score 494 ± 78 vs. score 377 ± 77, mean ± SD) ( ). Malignant effusions were well controlled, and the median time to progression (TTP) was 91 days and 111 days in MPE and MPCE, respectively. In addition, no severe side effects were observed, except in one patient with mild dizziness. In summary, the low dose of single bevacizumab (100 mg) with intrapleural or intrapericardial injection is effective and safe in the treatment of lung cancer-mediated malignant effusion, rapidly improving the malignant effusion-related symptoms and quality of life in patients with NSCLC.
- 31 October 2022
- Published by Hindawi Limited in Canadian Respiratory Journal
- Vol. 2022, 1-5
Open AccessEfficacy of Intrapleural or Intrapericardial Injection of Single Bevacizumab in the Treatment of Lung Cancer-Mediated Malignant Effusion
The usage of bevacizumab for malignant pleural effusion (MPE) or malignant pericardial effusion (MPCE) has attracted increasing interest from researchers, but the precise ways of bevacizumab administration remain unknown. Patients with histologically or cytologically confirmed non-small-cell lung cancer (NSCLC) with MPE or MPCE were enrolled in the study and treated with a low dose of single bevacizumab (100 mg) intrapleurally or intrapericardially injected after the drainage of the effusions. The Lung Cancer Symptom Scale (LCSS), efficacy, and safety of drug administration were used as evaluation parameters in this study. The results indicated that lung cancer-related symptoms were significantly improved following treatment, compared with symptoms before the treatment (LCSS, score 494 ± 78 vs. score 377 ± 77, mean ± SD) ( ). Malignant effusions were well controlled, and the median time to progression (TTP) was 91 days and 111 days in MPE and MPCE, respectively. In addition, no severe side effects were observed, except in one patient with mild dizziness. In summary, the low dose of single bevacizumab (100 mg) with intrapleural or intrapericardial injection is effective and safe in the treatment of lung cancer-mediated malignant effusion, rapidly improving the malignant effusion-related symptoms and quality of life in patients with NSCLC.